tiprankstipranks
Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50
PremiumThe FlySpyre Therapeutics 7.275M share Spot Secondary priced at $27.50
1M ago
Spyre Therapeutics Faces Internal Control Challenges
Premium
Company Announcements
Spyre Therapeutics Faces Internal Control Challenges
1M ago
Spyre Therapeutics announces $200M common stock offering
Premium
The Fly
Spyre Therapeutics announces $200M common stock offering
1M ago
Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
PremiumThe FlySpyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
1M ago
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
Premium
The Fly
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
2M ago
Spyre Therapeutics Advances SPY003 for IBD Treatment
Premium
Company Announcements
Spyre Therapeutics Advances SPY003 for IBD Treatment
2M ago
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
PremiumThe FlyWedbush bullish on Spyre Therapeutics, initiates with an Outperform
4M ago
Spyre Therapeutics initiated with an Outperform at Wedbush
Premium
The Fly
Spyre Therapeutics initiated with an Outperform at Wedbush
4M ago
Spyre Therapeutics management to meet with BTIG
Premium
The Fly
Spyre Therapeutics management to meet with BTIG
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100